Mankind Pharma Ltd

₹ 2,493 0.95%

30 Oct - close price

mankindpharma.com BSE: 543904 NSE: MANKIND F&O

About

Incorporated in 1995, Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations in various acute and chronic therapeutic areas and several consumer healthcare products.^[1]

Key Points

Leadership^[1]
- #1 Rank in Prescriptions over the last 8 yrs.
- #2 Rank by volume & #4 Rank by value in IPM
- 4 Consumer healthcare brands ranked #1 in their categories.

Website BSE NSE F&O

Market Cap ₹ 1,02,964 Cr.
Current Price ₹ 2,493
High / Low ₹ 2,642 / 1,910
Stock P/E 43.2
Book Value ₹ 397
Dividend Yield 0.04 %
ROCE 13.7 %
ROE 13.8 %
Face Value ₹ 1.00

Add ratio to table

Edit ratios

Pros

Company has reduced debt.

Cons

Promoter holding has decreased over last 3 years: -3.88%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 200 BSE Dollex 200 Nifty 500 Nifty Pharma Nifty Midcap 100 Nifty Midcap 50 Nifty 200 BSE 150 MidCap Index BSE 250 LargeMidCap Index BSE 400 MidSmallCap Index Nifty LargeMidcap 250 Nifty 500 Multicap 50:25:25 Nifty Healthcare Index Nifty Midcap 150 Nifty MidSmallcap 400 Nifty Total Market Nifty500 Shariah Nifty500 Multicap India Manufacturing 50:30:20 Nifty MidSmall Healthcare BSE 200 Equal Weight Nifty MidSmall India Consumption Nifty500 Equal Weight Nifty500 LargeMidSmall Equal-Cap Weighted BSE Select IPO BSE 1000 Nifty India FPI 150 Nifty500 Healthcare Nifty MidSmallcap400 50:50

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
	2,260	2,209	2,007	2,413	2,544	2,414	2,119	2,570	2,637	2,633	2,582	2,964	3,145
	1,662	1,636	1,482	1,837	1,781	1,668	1,778	1,885	1,933	1,854	1,663	2,035	2,213
Operating Profit	598	573	526	576	763	746	342	685	704	778	919	929	933
OPM %	26%	26%	26%	24%	30%	31%	16%	27%	27%	30%	36%	31%	30%
	84	92	109	125	139	70	220	65	78	-27	104	34	59
Interest	4	4	4	7	3	200	162	149	149	138	125	95	88
Depreciation	77	90	87	91	90	91	115	105	107	108	109	111	120
Profit before tax	601	571	543	603	810	525	284	496	526	505	788	757	784
Tax %	21%	15%	14%	16%	20%	22%	16%	16%	13%	11%	9%	26%	26%
	473	487	468	506	645	412	238	415	460	449	714	558	582
EPS in Rs	11.80	12.16	11.68	12.62	16.11	9.99	5.77	10.06	11.14	10.87	17.29	13.52	14.09
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	3,918	3,829	4,794	5,530	7,486	8,127	8,629	9,507	10,421	11,324
	3,141	3,124	3,550	4,151	5,644	6,429	6,358	7,082	7,333	7,765
Operating Profit	778	705	1,244	1,379	1,842	1,698	2,272	2,425	3,088	3,558
OPM %	20%	18%	26%	25%	25%	21%	26%	26%	30%	31%
	209	64	94	148	200	163	369	555	218	170
Interest	18	40	11	8	48	28	17	378	562	446
Depreciation	28	38	62	78	123	270	335	395	429	448
Profit before tax	941	691	1,265	1,440	1,871	1,563	2,289	2,208	2,315	2,833
Tax %	26%	26%	24%	25%	26%	20%	18%	19%	12%
	694	514	958	1,084	1,389	1,248	1,876	1,786	2,038	2,303
EPS in Rs	17.33	12.83	23.92	27.07	34.68	31.16	46.84	43.29	49.36	55.77
Dividend Payout %	0%	0%	32%	0%	0%	0%	0%	0%	2%

Compounded Sales Growth
10 Years:	%
5 Years:	14%
3 Years:	9%
TTM:	16%

Compounded Profit Growth
10 Years:	%
5 Years:	15%
3 Years:	20%
TTM:	56%

Stock Price CAGR
10 Years:	%
5 Years:	%
3 Years:	12%
1 Year:	5%

Return on Equity
10 Years:	%
5 Years:	16%
3 Years:	15%
Last Year:	14%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	40	40	40	40	40	40	40	41	41
Reserves	2,957	3,025	3,611	4,694	6,500	7,744	9,663	14,281	16,356
	360	190	3	101	688	5	24	7,383	5,571
	652	596	877	1,045	1,710	1,583	1,790	2,752	2,658
Total Liabilities	4,009	3,851	4,531	5,880	8,939	9,371	11,516	24,458	24,625
	534	778	945	987	2,927	3,142	3,552	4,076	3,926
CWIP	322	211	148	166	387	495	209	207	420
Investments	1,402	1,698	1,784	2,397	2,526	3,102	4,215	16,683	16,523
	1,751	1,164	1,655	2,330	3,100	2,632	3,540	3,491	3,756
Total Assets	4,009	3,851	4,531	5,880	8,939	9,371	11,516	24,458	24,625

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	540	537	960	1,022	821	1,799	1,736	2,350	2,752
	-516	-306	-396	-1,127	-1,360	-1,041	-1,665	-12,178	-388
	8	-240	-559	89	579	-710	-5	9,816	-2,477
Net Cash Flow	31	-9	5	-16	40	48	66	-11	-113
Free Cash Flow	309	371	795	830	-1,360	1,219	1,456	1,996	2,317
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	102%	111%	99%	103%	70%	123%	95%	116%	104%

Ratios

Standalone / View Consolidated

	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	23	13	32	24	23	22	33	35	41
Inventory Days	120	126	124	169	183	132	160	154	151
Days Payable	115	101	113	122	133	103	75	80	95
Cash Conversion Cycle	27	38	43	72	73	52	118	109	97
Working Capital Days	95	44	41	42	26	40	55	-81	-87
ROCE %		22%	36%	33%	30%	21%	24%	15%	14%

Insights

In beta

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Mar 2026

Chronic Share in Total Portfolio
%

xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx
x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx
				xx	xx	xx			xx	xx
								xx,xxx	xx,xxx	xx,xxx
								x.xx	x.xx	x.xx
						xx.xx
								x.xx

Please log in to see hidden values.

CVM (Covered Market) Share in Total IPM
%

Market Share by Value in IPM
%

Volume Share in IPM
%

Brand Families >INR 100 Cr
count

Field Force Size
count

Volume Growth
%

Prescription Share
%

R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
	76.50%	74.88%	74.87%	74.87%	72.71%	72.70%	72.67%	72.67%	72.66%	72.66%	72.63%	72.62%
	6.74%	9.87%	11.58%	12.37%	13.34%	12.92%	13.07%	12.83%	11.34%	10.24%	9.45%	9.37%
	9.78%	11.14%	9.94%	9.91%	11.05%	11.47%	11.50%	11.91%	13.26%	14.46%	15.39%	15.54%
	6.97%	4.10%	3.61%	2.86%	2.89%	2.89%	2.75%	2.57%	2.75%	2.63%	2.53%	2.46%
No. of Shareholders	1,27,449	1,35,116	1,53,450	1,63,854	1,71,281	1,80,597	1,79,549	1,70,347	1,77,539	1,77,606	1,66,715	1,63,770

	Mar 2024	Mar 2025	Mar 2026	Sep 2026
	74.88%	72.70%	72.66%	72.62%
	9.87%	12.92%	10.24%	9.37%
	11.14%	11.47%	14.46%	15.54%
	4.10%	2.89%	2.63%	2.46%
No. of Shareholders	1,35,116	1,80,597	1,77,606	1,63,770

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

DRHP

Credit ratings

Concalls

Oct 2026
Transcript PPT REC
Oct 2026

Transcript

AI Summary
PPT
Aug 2026
Transcript PPT REC
May 2026
Transcript PPT REC
Feb 2026
Transcript PPT REC
Nov 2025
Transcript PPT REC
Aug 2025
Transcript PPT REC
May 2025
Transcript PPT
Jan 2025
Transcript PPT
Nov 2024
Transcript PPT
Sep 2024

Transcript

AI Summary
PPT
Aug 2024

Transcript

AI Summary
PPT
Aug 2024
Transcript PPT
Aug 2024
Transcript PPT
Jul 2024

Transcript

AI Summary
PPT
May 2024
Transcript PPT
Feb 2024
Transcript PPT
Jan 2024

Transcript

AI Summary
PPT
Nov 2023
Transcript PPT
Aug 2023
Transcript PPT
Jun 2023
Transcript PPT